Overview and Scope
Monoclonal antibodies (MABS) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system.To kill them, they seek out the antigens (foreign substances) and adhere to them.
Sizing and Forecast
The monoclonal antibodies (mabs) market size has grown rapidly in recent years. It will grow from $234.37 billion in 2023 to $261.66 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to prevalence of chronic diseases, increasing investment in r&d, growing awareness of mabs, growing elderly population.
The monoclonal antibodies (mabs) market size is expected to see rapidly grown in the next few years. It will grow to $424.24 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to expanding therapeutic indications, personalized medicine, biosimilars and generics, combination therapies, pandemic preparedness, biopharmaceutical investment. Major trends in the forecast period include immunotherapy advancements, subcutaneous administration, next-generation antibodies, subcutaneous formulations, digital health integration, advancements in biotechnology.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Segmentation & Regional Insights
The monoclonal antibodies (mabs) market covered in this report is segmented –
1) By Source: Murine, Chimeric, Humanized, Human
2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications
3) By End Users: Hospitals, Private Clinics, Research Institute
North America was the largest region in the monoclonal antibodies (MAbS) market in 2023. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=2554&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibody market’s growth. The biosimilars’ aim is to curb the increasing cost of healthcare and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% less than the original biologic drug. The number of clinical trials for a biosimilar is comparatively smaller than that of the original biologic drug, and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘˜Guidelines on Similar Biologics’™ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.
Key Industry Players
Major companies operating in the monoclonal antibodies (MABS) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Mylan N.V., Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc
The monoclonal antibodies (mas) market report table of contents includes:
1. Executive Summary
2. Monoclonal Antibodies (MAs) Market Characteristics
3. Monoclonal Antibodies (MAs) Market Trends And Strategies
4. Monoclonal Antibodies (MAs) Market – Macro Economic Scenario
5. Global Monoclonal Antibodies (MAs) Market Size and Growth
.
.
.
31. Global Monoclonal Antibodies (MAs) Market Competitive Benchmarking
32. Global Monoclonal Antibodies (MAs) Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAs) Market
34. Monoclonal Antibodies (MAs) Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
